Amgen Inc. (AMGN)

190.47
1.30 0.67
NASDAQ : Health Technology
Prev Close 191.76
Open 191.48
Day Low/High 189.49 / 191.48
52 Wk Low/High 163.31 / 201.23
Volume 2.21M
Avg Volume 2.94M
Exchange NASDAQ
Shares Outstanding 661.71M
Market Cap 127.58B
EPS 2.70
P/E Ratio 61.21
Div & Yield 5.28 (2.55%)

Latest News

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Amgen Is Ready to Breakout on the Upside

Amgen Is Ready to Breakout on the Upside

Let's go to the charts.

Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine

Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine

Results From a One-Year Study of Efficacy and Safety of Aimovig in Chronic Migraine and Data From a Three-Year Analysis Assessing Safety and Tolerability of Aimovig in Episodic Migraine Will be Presented at the American Headache Society Annual Meeting

Amgen And Health And Benefits Consultant Piper Jordan Partner On First Migraine Project With Employers

Amgen And Health And Benefits Consultant Piper Jordan Partner On First Migraine Project With Employers

$11 Billion is Estimated to be Lost by American Employers Each Year Due to Migraine

Amgen And Novartis Highlight Findings From A Large Global Patient Survey Revealing That Worldwide Approximately 60 Percent Of Employed People With Migraine Missed, On Average, A Week Of Work In A Month

Amgen And Novartis Highlight Findings From A Large Global Patient Survey Revealing That Worldwide Approximately 60 Percent Of Employed People With Migraine Missed, On Average, A Week Of Work In A Month

The My Migraine Voice Survey Involved More Than 11,000 People Globally, 10 Percent of Which Were From the U.S., and Highlights Urgent Need for Better Care for Benefit of Patients and Society

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab

Study Evaluated Efficacy and Safety of ABP 710 Compared With Infliximab in Patients With Moderate-to-Severe Rheumatoid Arthritis

New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

Data Presented at the 78th Scientific Sessions of the American Diabetes Association

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label

BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.

The New #41 Most Shorted Nasdaq 100 Component: Amgen

The New #41 Most Shorted Nasdaq 100 Component: Amgen

The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label

KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months

European Commission Approves Prolia® (denosumab) For Patients With Glucocorticoid-Induced Osteoporosis

European Commission Approves Prolia® (denosumab) For Patients With Glucocorticoid-Induced Osteoporosis

Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures

Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

THOUSAND OAKS, Calif., June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39 th Annual Global Healthcare Conference at 9:30 a.

Amgen, Oklahoma Health Care Authority And University Of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes

Amgen, Oklahoma Health Care Authority And University Of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes

Amgen's First Public-Private Partnership with a State Medicaid Agency to Help Improve Patient Health Care Needs Through Data, Science and Information

Dow Finishes Slightly Lower as Nasdaq Jumps to Another Record Close

Dow Finishes Slightly Lower as Nasdaq Jumps to Another Record Close

Stocks are mixed Tuesday but traders continue to snap up tech stocks.

Nasdaq's on Fire: Cramer's 'Mad Money' Recap (Monday 6/4/18)

Nasdaq's on Fire: Cramer's 'Mad Money' Recap (Monday 6/4/18)

Jim Cramer talks about the stocks and sectors behind the resurgence fueling the Nasdaq's gains.

Jim Cramer: Move Over FANG, Long Live INJFANG

Jim Cramer: Move Over FANG, Long Live INJFANG

The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Jim Cramer says the market like this economy; he has your game plan for next week.

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 Mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 Mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 Mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 Mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma

Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers

Efforts to Focus on Pre-Clinical and Clinical Research for up to 16 Early-Stage Programs Across Various Types of Cancer

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMGN, CIG.C, COTV, CTRE, GMS, HPT, IAG, NFEC, QGEN, SCVL, THR, TPHS, USFD, UVV Downgrades: BKE, IGT, TSLX, VRX Initiations: MGEN Read on to get TheStreet Quant Ratings' detailed report:

Emboldened By Biotech Names

Emboldened By Biotech Names

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

Public-Private Partnership Aims to Connect Underserved Cancer Patients to Enhanced Symptom Management Support Through the Use of Connected Technologies

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Here's what you need to know now for Friday, May 18.

TheStreet Quant Rating: B (Buy)